Quantitative analysis for COMPASS Pathways plc (CMPS) — Health Care: AI-powered alpha score, Benjamin Graham intrinsic value, ML-based forecast, technical and fundamental signals, and insider activity.
Current Q-Score verdict: Buy (62.0) (grade B). 30 signals analyzed (25 differentiated alt-data).
CMPS stock price is tracked daily for technical and fundamental analysis. The data below shows recent trading activity used in trend analysis, momentum calculation, and entry/exit signals.
| Date | High | Low | Close |
|---|---|---|---|
| 2026-04-29 | $8.57 | $8.25 | $8.38 |
| 2026-05-11 | $9.97 | $9.55 | $9.65 |
| 2026-05-21 | $12.03 | $10.70 | $11.59 |
| 2026-06-03 | $13.36 | $12.50 | $12.69 |
| 2026-06-15 | $12.49 | $11.64 | $11.79 |
| 2026-06-26 | $14.94 | $13.34 | $14.82 |
| 2026-07-09 | $14.04 | $13.46 | $13.60 |
| 2026-07-21 | $12.26 | $11.48 | $12.18 |
| 2026-07-31 | $11.79 | $11.20 | $11.35 |
| 2026-08-12 | $14.59 | $13.65 | $14.22 |
| 2026-08-24 | $14.32 | $13.08 | $14.20 |
| 2026-09-03 | $13.30 | $12.73 | $13.29 |
How COMPASS Pathways plc stacks up against same-sector peers on market capitalization and alpha scores:
| Ticker | Company | Market Cap | Alpha Score |
|---|---|---|---|
| ALVO | Alvotech | $1.0B | — |
| BTX | BlackRock Technology and Private Equity Term Trust | $1.0B | — |
| CRON | Cronos Group Inc. | $998M | — |
| DRTS | Alpha Tau Medical Ltd. | $984M | — |
View all Health Care stocks by valuation and signals →
COMPASS Pathways plc (CMPS) scores Buy (62.0), and the composite conceals a 89-point disagreement between its dimensions. It is strongest on analyst consensus at 90, and weakest on competitive moat at 1. A stock can carry analyst consensus that high while competitive moat sits at 1; the composite averages that tension away, which is why the breakdown is worth reading before the headline number. See Q-Score methodology for how these dimensions are weighted and combined.
| Dimension | Score |
|---|---|
| analyst consensus | 90 |
| technicals | 53 |
| competitive moat | 1 |
StoQuant analyzes 30 signals (25 alt-data). Alternative data sources (FDA approvals, GitHub activity, SEC filings, App Store ratings) complement traditional financial metrics.
All StoQuant signals are explained in our knowledge base:
Health Care Hub — Top performers and valuation outliers in Health Care
Get daily updates on COMPASS Pathways plc (CMPS): Q-Score changes, insider transactions, forecast shifts, sector rotation, and macroeconomic context. The StoQuant digest curates the most material signals for your watchlist — free, no account required.
See a sample digest • Unsubscribe anytime • Privacy policy
StoQuant is a quantitative stock research platform powered by AI scoring, fundamental analysis, and institutional-grade signals. We cover 3,600+ US-listed equities with daily updates on valuations, earnings quality, insider flow, and ML-based return forecasts. Learn more about us.
Share this stock's latest Q-Score and alpha score on your website, GitHub README, or blog. The SVG badge auto-updates daily:
<a href="https://stoquant.com/research/CMPS"><img src="https://stoquant.com/badge/CMPS.svg" alt="COMPASS Pathways plc (CMPS) Q-Score and Alpha on StoQuant" width="240" height="64" /></a>
StoQuant research is generated algorithmically using public market data, SEC filings, news feeds, and proprietary ML models. Not investment advice. Past performance does not guarantee future results.
Weekly Q-Score signals and insider buying activity on our highest-conviction stock picks. Email only, no account needed. See a sample digest.